AbbVie Says Elahere Gets Approval From European Commission as Ovarian Cancer Treatment

MT Newswires Live11-18

AbbVie (ABBV) said Monday the European Commission has granted marketing authorization for Elahere to treat adult patients with a specific type of platinum-resistant ovarian, fallopian tube or primary peritoneal cancer who have received one to three prior systemic treatment regimens.

The company said Elahere is the first and only novel therapy approved in the European Union for patients with folate receptor-alpha positive, platinum-resistant ovarian cancer

AbbVie is collaborating with Roche Diagnostics on a companion diagnostic test to identify patients who may be eligible for Elahere.

The marketing authorization of Elahere is supported by data from a phase 3 trial, which demonstrated its overall survival benefit with a 33% reduction in the risk of death compared with chemotherapy, AbbVie said.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment